uniQure N.V. Ordinary Shares vs Health Care Select Sector SPDR Fund — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while Health Care Select Sector SPDR Fund trades at $175.09 (market cap $44.49B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 30.1× uniQure N.V. Ordinary Shares's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| QURE | XLV | |
|---|---|---|
Market Cap | $1.48B | $44.49B |
Volume | 2,488,780 | 8,745,019 |
Sector | Health | — |
52-Week High | $70.59 | $175.68 |
52-Week Low | $9.03 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $728.62M | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLV trades at $169.66, down 1.35% on the day, while maintaining a bullish technical outlook with strong moving average support. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 60 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and its competitive positioning against peer healthcare ETFs.
The ETF offers defensive growth exposure with healthcare sector stability, though elevated RSI levels suggest near-term consolidation. Political volatility and pharmaceutical trial failures present sector-specific risks, while XLV's technical strength and institutional interest support continued upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →